Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ortec launches OrCel through PDI:

This article was originally published in Clinica

Executive Summary

Ortec International is to launch OrCel, a biologically active wound agent, from this quarter, with a dedicated sales force from sales and marketing company PDI. The two companies will target the $100 million donor site burn market. New York-based Ortec says its product is the only one containing living human cells that is FDA-approved for healing donor site wounds in burn patients. At a later stage, Ortec plans "a collaboration with or acquisition by a large, woundcare focused marketing and distribution company" for the venous and diabetic ulcer markets.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts